Skip to main content

Table 4 Clinical performance of the most efficient test to detect CIN1+, CIN2+ and CIN3+ lesions

From: Combining HPV DNA load with p16/Ki-67 staining to detect cervical precancerous lesions and predict the progression of CIN1–2 lesions

 

HPV infection

Test

Sensitivity (%)

Specificity (%)

PPV (%)

NPV (%)

CINI+

no

p16/Ki-67

88.64 (75.4–96.2)

51.43 (34–68.6)

69.9 (64.6–75)

78.2 (68.5–85.7)

 

HPV-16 and/or 58

p16/Ki-67/HPV load

90.8 (85.3–94.3)

86.96 (66.4–97.2)

98 (95.1–99.3)

57.1 (47.8–62.5)

 

others

p16/Ki-67

81.36 (69.1–90.3)

84.63 (65.1–95.6)

92.3 (85.5–97.6)

66.67 (58.1–73.9)

CINII+

no

p16/Ki-67

94.12 (71.3–99.9)

88.71 (78.1–95.3)

69.6 (54.8–80)

98.2 (92.2–100)

 

HPV-16 and/or 58

p16/Ki-67/HPV load

88.89 (82.3–93.6)

92.16 (81.1–97.8)

95.8 (92.6–99.1)

75.8 (67.6–82)

 

others

p16

94.59 (81.8–99.3)

75 (60.4–86.4)

74.5 (65.9–82.3)

94.7 (86–99)

CINIII+

no

p16/Ki-67

100 (47.8–100)

90.54 (81.5–96.1)

41.7 (26.7–44.4)

100 (96.5–100)

 

HPV-16 and/or 58

p16/Ki-67/HPV load

86.6 (78.2–92.7)

77.53 (67.4–85.7)

80.8 (75.6–85.4)

84.1 (78.4–89.6)

 

others

p16/Ki-67

84.21 (60.4–96.6)

96.97 (89.5–99.6)

88.9 (72.4–97.5)

95.5 (89.8–99)